







an Open Access Journal by MDPI

The Promising Future of Anti-tumor Drugs

Guest Editor:

Dr. Mohammed M. Alanazi

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

Deadline for manuscript submissions:

closed (31 October 2023)

Message from the Guest Editor

The major challenge in the cancer therapy is the development of multidrug resistance and relapse. Conventional anticancer drugs directly target the DNA of the cell, while modern chemotherapeutic drugs include molecular-targeted therapy. Targeted chemotherapy has been effective in several malignancies; however, the success has always been limited by drug resistance and/or side effects. To this end, there is an urgent need for the identification of predictive anticancer agents that may fight cancer with multi-targeted pathways, lower side effects, and/or have higher selectivity. We are pleased to invite you to contribute to our Special Issue which aims to collect contributions on the development of new anticancer agents. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: Design and synthesis of novel anticancer agents; Drug repurposing in the development of anticancer agents; Virtual screening of novel anticancer agents; Computer-aided drug design of novel anticancer agents; Anticancer drug discovery through plant extraction; Investigation on the pharmacological actions of anticancer drugs, etc.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed,

MEDLINE, PMC, and other databases.

Journal Rank: CiteScore - Q2 (General Medicine)

Contact Us